Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer

European Journal of Cancer

Volumn 48, Issue 4, 2012, Pages 510-517

  Schonnemann K R ^a,c   Yilmaz, M ^b   Bjerregaard, J K ^a,c   Nielsen, K M ^b   Pfeiffer, P ^a,c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cetuximab; Irinotecan; Second line treatment; Stomach cancer

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ONDANSETRON; OXALIPLATIN; PLATINUM; PREDNISOLONE;

ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84857043129     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.005     Document Type: Article

References (38)

1. D.M. Parkin, F. Bray, and J. Ferlay Global CANCER Statistics 2002 CA Cancer J Clin 55 2005 47 108
2. A. Klint, G. Engholm, and H.H. Storm Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964-2003 followed up to the end of 2006 Acta Oncol 49 2010 578 607
3. S. Pyrhonen, T. Kuitunen, and P. Nyandoto Randomized comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 1995 587 589
4. B. Glimelius, K. Ekström, and K. Hoffman Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 1997 163 168 (Pubitemid 27112884)
5. I. Chau, A.R. Norman, and D. Cunningham Is there a differential chemotherapy effect in patients with locally advanced or metastatic oesophageal (O), oesophago-gastric junction (OGJ) and gastric (G) adenocarcinoma? A pooled analysis of four randomised controlled trials (RTCs) J Clin Oncol 2007 abstract 75
6. A. Webb, D. Cunningham, and J.H. Scarffe Randomized trial comparing epirubicin, cisplatin and fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 1997 261 2676
7. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
8. E. Van Cutsem, V.M. Moiseyenko, and S. Tjulandin Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 2006 4991 4997 (Pubitemid 46631401)
9. A.D. Wagner, S. Unverzagt, and W. Grothe Chemotherapy for advanced gastric cancer Cochrance database Syst Rev 17 3 2010 CD004064 Review
10. A. Tanizawa, A. Fujimori, and Y. Fujimori Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials J Natl cancer Inst 86 11 1994 836 842 (Pubitemid 24164661)
11. J.H. Chun, H.K. Kim, and J.S. Lee Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy Jpn J Clin Oncol 34 2004 8 13 (Pubitemid 43118052)
12. P.C. Thuss-Patience, T. Kretzschmar, and D. Bichev Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer. A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 4 2011 [Epub ahead of print]
13. S.H. Park, D.H. Lim, and K. Park A multicenter, randomized phase III trial comparing second-lie chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC) J Clin Oncol 2011 [abstract 4004, Epub ahead of print]
14. T. Takehana, K. Kunitomo, and S. Suzuki A. Expression of epidermal growth factor receptor in gastric carcinomas Clin Gastroenterol Hepatol 1 6 2003 438 445 (Pubitemid 37413607)
15. M.A. Kim, H.S. Lee, and H.E. Lee EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number Histopathology 52 6 2008 738 746 (Pubitemid 351600058)
16. J. Tabernero, P. Pfeiffer, and A. Cervantes Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 13 2008 113 119 (Pubitemid 351342574)
17. R.K. Ramanathan Alternative dosing schedules for cetuximab: a role for biweekly administration? Clin Colorectal Cancer 7 2008 364 368
18. M. Czeka, B. Gruenberger, and A. Kiss Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer Anticancer Res 30 2010 2355 2360
19. J. Gold, B. Goldman, and S. Iqbal Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma J Thor Oncol 5 2010 1472 1476
20. J.A. Chan, L.S. Blaszkowsky, and P.C. Enzinger A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma Ann Oncol 22 2011 1367 1373
21. P. Pfeiffer, D. Nielsen, and J. Bjerregaard Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil Ann Oncol 19 2008 1141 1145 (Pubitemid 351796340)
22. I. Chau, A.R. Norman, and D. Cunningham Multivariate prognostic factor analysis in locally advanced and metastatic esophagus-gastric cancer - pooled analysis from three multicentre randomized controlled trials using individual patient data J Clin Oncol 22 2004 2395 2403 (Pubitemid 41121931)
23. D. Wilson, L. Hillert, and J.I. Geh Review of second-line chemotherapy for advanced gastric adenocarcinoma Clin Oncol 17 2005 81 91
24. J. Lee, T. Lim, and J.E. Uhm Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann Oncol 18 2007 886 891 (Pubitemid 47054086)
25. J.A. Ajani, J. Baker, and P.W. Pisters Irinotecan plus cisplatin in advanced gastric or gastro esophageal junction carcinoma Oncology (Williston Park) 15 2001 52 54 (Pubitemid 33739185)
26. S.J. Sym, H.M. Chang, and H.J. Kang A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer Cancer Chem Pharm 63 2008 1 8
27. D.Y. Kim, J.H. Kim, and S.H. Lee Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer Ann Oncol 14 2003 383 387 (Pubitemid 36367414)
28. K.R. Schønnemann, H.A. Jensen, and M. Yilmaz Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first- line therapy in patients with non-resectable gastric cancer Br J cancer 99 2008 858 860
29. M. Andersen, K.R. Schønnemann, and M. Yilmaz Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer Acta Oncol 49 8 2010 1246 1252
30. C. Pinto, F. Di Fabio, and S. Siena Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastro esophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 2007 110 117
31. C. Pinto, F. Di Fabio, and C. Barone Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) Br J cancer 101 8 2009 1261 1268
32. M. Moehler, A. Mueller, and T. Trarbach Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study Ann Oncol 22 2011 1358 1366
33. C. Kim, J.I. Lee, and M.H. Ruy A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer Invest New Drugs 29 2011 366 373
34. S.W. Han, D.Y. Oh, and S.A. Im Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer Br J cancer 100 2009 298 304
35. F. Lordick, B. Luber, and S. Lorenzen Cetuximab plus oxaliplatin/5- flouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Br J cancer 102 2010 500 505
36. A. Stein, S. Peinert, S.E. Al-Batran, and D. Arnold Targeting Epithelial Growth Factor Receptor (EGFR) with cetuximab in Combination with irinotecan as salvage treatment in refractory gastric cancer patients: a retrospective analysis and review of the literature Eur J Clin Med Onc 3 1 2011
37. S.R. Park, M. Kook, and L.J. Choi Predictive factors for efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients Cancer Chem Pharm 65 2010 579 587
38. K.R. Schønnemann, J.K. Bjerregaard, and T.P. Hansen Biweekly cetuximab and irinotecan as second-line therapy in patients with gastroesophageal cancer previously treated with platinum Gastric cancer 14 2011 219 225